Differential Target Multiplexed™ SCS therapy Education & training

Differential Target Multiplexed™ SCS is a superior spinal cord stimulation (SCS) therapy delivered via the Intellis™ SCS platforms to treat patients with chronic, intractable back and leg pain.

Read the published RCT

Differential Target Multiplexed™ SCS therapy

Differential Target Multiplexed™ (DTM) spinal cord stimulation (SCS) is a proprietary therapy inspired by science and rooted in pre-clinical research, and adapted to provide superior clinical outcomes.




The Differential Target Multiplexed™ SCS 12-month RCT proved sustained superiority compared to conventional stimulation.

DTM™ SCS 12-month RCT Data

* Descriptive comparison, including studies with similar design (RCT; randomization >100 subjects; comparing 2 SCS therapies; with at least 12-months follow up) and patient populations (inclusion/exclusion criteria; baseline demographics) with back pain responder rates reported. This is not based on a statistical analysis of outcomes between studies.

Proven only on the Intellis™ platform

Intellis size comparison product image

DTM™ SCS webinar series

Watch the webinars below to learn more about the evolution of DTM™ SCS and its impact on patients.

DTM™ SCS therapy options

DTM™ SCS endurance therapy offers meaningful relief with lower energy settings.

Vectors study results

Vectors is a study of targeted stimulation parameters in SCS designed to evaluate the long-term efficacy of the therapy when the Evolve™ workflow is used.

Vanta™ SCS neurostimulator

High performance and recharge-free. Experience DTM™ SCS endurance therapy on Vanta™ neurostimulator.


Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009 Jan;10(1):23-36.


Vallejo R, Tilley DM, Vogel L, Benyamin R. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract. 2010 10(3):167-184.


De Leo JA, Tawfik VL, LaCroix-Fralish ML. The tetrapartite synapse: Path to CNS centralization and chronic pain. Pain. 2006;122:17-21.


Ruiz-Sauri A., Orduña-Valls J.M., Blasco-Serra A. et al. Glia to neuron ratio in the posterior aspect of the human spinal cord at thoracic segments relevant to spinal cord stimulation. Journal of Anatomy, 2019;235(5)997-1006.


Vallejo R, Kelley CA, Gupta A, Smith WJ, Vallejo A, Cedeño DL. Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain. Mol Pain. 2020;16:1744806920918057.


Cedeno DL, Smith WJ, Kelley CA, Vallejo R. Spinal cord stimulation using differential target multiplexed programming modulates neural cell-specific transcriptomes in an animal model of neuropathic pain. Mol Pain. 2020;16:1744806920964360. 


Smith WJ, Cedeño DL, Thomas SM, et al. Modulation of microglial activation states by spinal cord stimulation in an animal model of neuropathic pain: Comparing high rate, low rate, and differential target multiplexed programming. Mol Pain. 2021;17:1744806921999013. 


Vallejo R, Tilley D, Kelley C, et al. proteomics of differential target multiplexed-SCS applied to an animal model of neuropathic pain. American Society for Regional Anesthesiology and Pain Medicine (ASRA); 2019; New Orleans, LA. Abstract #509


Fishman M, Cordner H, Justiz R, et al.  12-Month Results from multicenter, open-label, randomized controlled clinical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021; 00: 1– 12. doi: 10.1111/papr.13066.